317 related articles for article (PubMed ID: 35616802)
1. Monoclonal antibody designed for SARS-nCoV-2 spike protein of receptor binding domain on antigenic targeted epitopes for inhibition to prevent viral entry.
Abduljaleel Z; Shahzad N; Aziz SA; Malik SM
Mol Divers; 2023 Apr; 27(2):695-708. PubMed ID: 35616802
[TBL] [Abstract][Full Text] [Related]
2. Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain.
Yang M; Li J; Huang Z; Li H; Wang Y; Wang X; Kang S; Huang X; Wu C; Liu T; Jia Z; Liang J; Yuan X; He S; Chen X; Zhou Z; Chen Q; Liu S; Li J; Zheng H; Liu X; Li K; Yao X; Lang B; Liu L; Liao HX; Chen S
Microbiol Spectr; 2021 Oct; 9(2):e0135221. PubMed ID: 34643438
[TBL] [Abstract][Full Text] [Related]
3. Key residues of the receptor binding motif in the spike protein of SARS-CoV-2 that interact with ACE2 and neutralizing antibodies.
Yi C; Sun X; Ye J; Ding L; Liu M; Yang Z; Lu X; Zhang Y; Ma L; Gu W; Qu A; Xu J; Shi Z; Ling Z; Sun B
Cell Mol Immunol; 2020 Jun; 17(6):621-630. PubMed ID: 32415260
[TBL] [Abstract][Full Text] [Related]
4. Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody.
Tian X; Li C; Huang A; Xia S; Lu S; Shi Z; Lu L; Jiang S; Yang Z; Wu Y; Ying T
Emerg Microbes Infect; 2020; 9(1):382-385. PubMed ID: 32065055
[TBL] [Abstract][Full Text] [Related]
5. Characterization of a neutralizing antibody that recognizes a loop region adjacent to the receptor-binding interface of the SARS-CoV-2 spike receptor-binding domain.
Anzai I; Fujita J; Ono C; Kosaka Y; Miyamoto Y; Shichinohe S; Takada K; Torii S; Taguwa S; Suzuki K; Makino F; Kajita T; Inoue T; Namba K; Watanabe T; Matsuura Y
Microbiol Spectr; 2024 Apr; 12(4):e0365523. PubMed ID: 38415660
[TBL] [Abstract][Full Text] [Related]
6. Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine.
Tai W; He L; Zhang X; Pu J; Voronin D; Jiang S; Zhou Y; Du L
Cell Mol Immunol; 2020 Jun; 17(6):613-620. PubMed ID: 32203189
[TBL] [Abstract][Full Text] [Related]
7. Generation and utility of a single-chain fragment variable monoclonal antibody platform against a baculovirus expressed recombinant receptor binding domain of SARS-CoV-2 spike protein.
Salem R; El-Kholy AA; Waly FR; Ayman D; Sakr A; Hussein M
Mol Immunol; 2022 Jan; 141():287-296. PubMed ID: 34915268
[TBL] [Abstract][Full Text] [Related]
8. Structures and therapeutic potential of anti-RBD human monoclonal antibodies against SARS-CoV-2.
Huang KA; Zhou D; Tan TK; Chen C; Duyvesteyn HME; Zhao Y; Ginn HM; Qin L; Rijal P; Schimanski L; Donat R; Harding A; Gilbert-Jaramillo J; James W; Tree JA; Buttigieg K; Carroll M; Charlton S; Lien CE; Lin MY; Chen CP; Cheng SH; Chen X; Lin TY; Fry EE; Ren J; Ma C; Townsend AR; Stuart DI
Theranostics; 2022; 12(1):1-17. PubMed ID: 34987630
[No Abstract] [Full Text] [Related]
9. De novo design and Rosetta-based assessment of high-affinity antibody variable regions (Fv) against the SARS-CoV-2 spike receptor binding domain (RBD).
Boorla VS; Chowdhury R; Ramasubramanian R; Ameglio B; Frick R; Gray JJ; Maranas CD
Proteins; 2023 Feb; 91(2):196-208. PubMed ID: 36111441
[TBL] [Abstract][Full Text] [Related]
10. Epitope Profiling Reveals the Critical Antigenic Determinants in SARS-CoV-2 RBD-Based Antigen.
Jiang M; Zhang G; Liu H; Ding P; Liu Y; Tian Y; Wang Y; Wang A
Front Immunol; 2021; 12():707977. PubMed ID: 34621266
[TBL] [Abstract][Full Text] [Related]
11. Computational Analysis of Mutations in the Receptor-Binding Domain of SARS-CoV-2 Spike and Their Effects on Antibody Binding.
Bozdaganyan ME; Shaitan KV; Kirpichnikov MP; Sokolova OS; Orekhov PS
Viruses; 2022 Jan; 14(2):. PubMed ID: 35215888
[TBL] [Abstract][Full Text] [Related]
12. Receptor-binding domain of severe acute respiratory syndrome coronavirus spike protein contains multiple conformation-dependent epitopes that induce highly potent neutralizing antibodies.
He Y; Lu H; Siddiqui P; Zhou Y; Jiang S
J Immunol; 2005 Apr; 174(8):4908-15. PubMed ID: 15814718
[TBL] [Abstract][Full Text] [Related]
13. Neutralizing Monoclonal Antibodies Inhibit SARS-CoV-2 Infection through Blocking Membrane Fusion.
Li CJ; Chao TL; Chang TY; Hsiao CC; Lu DC; Chiang YW; Lai GC; Tsai YM; Fang JT; Ieong S; Wang JT; Chang SY; Chang SC
Microbiol Spectr; 2022 Apr; 10(2):e0181421. PubMed ID: 35293796
[TBL] [Abstract][Full Text] [Related]
14. Targeting SARS-CoV2 Spike Protein Receptor Binding Domain by Therapeutic Antibodies.
Hussain A; Hasan A; Nejadi Babadaei MM; Bloukh SH; Chowdhury MEH; Sharifi M; Haghighat S; Falahati M
Biomed Pharmacother; 2020 Oct; 130():110559. PubMed ID: 32768882
[TBL] [Abstract][Full Text] [Related]
15. Neutralization of SARS-CoV-2 requires antibodies against conformational receptor-binding domain epitopes.
Gattinger P; Niespodziana K; Stiasny K; Sahanic S; Tulaeva I; Borochova K; Dorofeeva Y; Schlederer T; Sonnweber T; Hofer G; Kiss R; Kratzer B; Trapin D; Tauber PA; Rottal A; Körmöczi U; Feichter M; Weber M; Focke-Tejkl M; Löffler-Ragg J; Mühl B; Kropfmüller A; Keller W; Stolz F; Henning R; Tancevski I; Puchhammer-Stöckl E; Pickl WF; Valenta R
Allergy; 2022 Jan; 77(1):230-242. PubMed ID: 34453317
[TBL] [Abstract][Full Text] [Related]
16. Design of a bifunctional pan-sarbecovirus entry inhibitor targeting the cell receptor and viral fusion protein.
Jin H; Cheng L; Gong Y; Zhu Y; Chong H; Zhang Z; He Y
J Virol; 2023 Aug; 97(8):e0019223. PubMed ID: 37578234
[TBL] [Abstract][Full Text] [Related]
17. Plant-produced SARS-CoV-2 receptor binding domain (RBD) variants showed differential binding efficiency with anti-spike specific monoclonal antibodies.
Rattanapisit K; Bulaon CJI; Khorattanakulchai N; Shanmugaraj B; Wangkanont K; Phoolcharoen W
PLoS One; 2021; 16(8):e0253574. PubMed ID: 34379620
[TBL] [Abstract][Full Text] [Related]
18. Effects of human anti-spike protein receptor binding domain antibodies on severe acute respiratory syndrome coronavirus neutralization escape and fitness.
Sui J; Deming M; Rockx B; Liddington RC; Zhu QK; Baric RS; Marasco WA
J Virol; 2014 Dec; 88(23):13769-80. PubMed ID: 25231316
[TBL] [Abstract][Full Text] [Related]
19. Novel human neutralizing mAbs specific for Spike-RBD of SARS-CoV-2.
Passariello M; Gentile C; Ferrucci V; Sasso E; Vetrei C; Fusco G; Viscardi M; Brandi S; Cerino P; Zambrano N; Zollo M; De Lorenzo C
Sci Rep; 2021 May; 11(1):11046. PubMed ID: 34040046
[TBL] [Abstract][Full Text] [Related]
20. Cross-neutralization of human and palm civet severe acute respiratory syndrome coronaviruses by antibodies targeting the receptor-binding domain of spike protein.
He Y; Li J; Li W; Lustigman S; Farzan M; Jiang S
J Immunol; 2006 May; 176(10):6085-92. PubMed ID: 16670317
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
